Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM

Clinical Trial ID NCT00597493

PubWeight™ 3.66‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00597493

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 2011 1.38
2 Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther 2010 1.23
3 Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets 2010 1.07
Next 100